By Spondylitis Association of America
The purpose of the trial is to study the safety and efficacy of Tildrakizumab in those with psoriatic arthritis (PsA), ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA).
A recent study published in the Journal of Dermatology sought to examine the progression of psoriasis to psoriatic spondylitis, examine the impact of psoriasis on the severity and manifestation of axial (spinal) symptoms, and identify factors that impact the efficacy of biologic medications.
On February 12, 2019 SAA hosted our very first twitter chat. We had a wonderful time discussing the topics of overcoming obstacles, healthy relationships, and balancing life & responsibilities while living with #spondylitis. Did you miss our chat? Below we share the content of the chat with our community. Enjoy!
This study will evaluate the natural history of spondyloarthritis (SpA) in children and adults. Researchers will study early signs and symptoms of axial spondyloarthritis to better understand the cause and progression of this disease, and in addition, compare genetic data of patients with that of healthy family members’ to help identify the genes involved in SpA, and their functions.
We’re very excited to announce the first ever Global Spondyloarthritis Summit! Join us online on Friday, May 3rd through Sunday, May 5th 2019.
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.